MedWatch

Novo Nordisk drags competitor to court over Saxenda copies

According to Novo Nordisk, a firm based in India has made a copy of its obesity drug, Saxenda. Novo is now fighting to get the copy off the market in a US court.

Photo: Novo Nordisk / PR

Novo Nordisk has summoned Orbicular Pharmaceutical Technologies before a court in Delaware in the US to block the launch of a generic copy of its obesity drug, Saxenda, Bloomberg News reports.

In the case, Novo Nordisk claims that a generic copy of Saxenda would violate 18 of Novo’s patents on the injectable obesity drug.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs